Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.

摘要: OBJECTIVE: To assess the characteristics of combination antiretroviral therapy (cART) administered concomitantly with chemotherapy and to establish prognostic determinants patients AIDS-related non-Hodgkin's lymphoma. METHODS: The study included 91 lymphoma from Swiss HIV Cohort Study enrolled between January 1997 October 2003, excluding lymphomas brain. We extracted lymphoma- HIV-specific variables at time diagnosis as well treatment changes over charts database. Cox regression analyses were performed predictors overall progression-free survival. RESULTS: During a median follow up 1.6 years, 57 died or progressed. Thirty-five stopped prematurely (before sixth cycle) usually due disease progression; these had shorter survival than those who completed six more cycles (14 versus 28 months). Interruptions cART decreased 35% before 5% during chemotherapy. Factors associated CD4+ T-cell count (<100 cells/microl) (hazard ratio [HR] 2.95 [95% confidence interval (CI) 1.53-5.67], hepatitis C seropositivity (HR 2.39 CI 1.01-5.67]), international index score 1.98-3.62 across categories) Burkitt histological subtypes 2.56 1.13-5.78]). CONCLUSIONS: not induced by effect interruptions on prognosis remains unclear, however, emerged-as predictor death beyond well-known count.